Welcome to our dedicated page for ASEP MED HLDGS news (Ticker: SEPSF), a resource for investors and traders seeking the latest updates and insights on ASEP MED HLDGS stock.
Asep Medical Holdings Inc. (SEPSF) is a leading company dedicated to addressing the global issue of antibiotic failure through innovative solutions for unmet medical needs. The company comprises three private companies with advanced technologies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. Sepset Biosciences focuses on early sepsis identification, ABT Innovations on biofilm infections, and SafeCoat Medical on antimicrobial coatings for medical devices. The company's groundbreaking AI-based technologies and diagnostic tools aim to revolutionize the medical industry.
Asep Medical Holdings Inc. (OTCQB: SEPSF) announced a joint venture with Sansure Biotech Inc. on January 27, 2023, aimed at commercializing the SepsetER sepsis diagnostic kit in China. The agreement, signed on September 29, 2022, outlines collaboration terms for research, development, and sublicensing in the Chinese market. Sansure will invest capital and Asep will receive royalties on sales. With a high sepsis mortality rate in China, this partnership is positioned to offer advanced diagnostic solutions, enhancing early detection capabilities while potentially reducing antibiotic resistance.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) announced an online webinar on January 24, 2023, at 1:00 pm EST, to discuss global market developments, scientific advances, and investment milestones. Key topics include updates on the acquisition of SafeCoat Medical Inc., a joint venture with Bahrain's Seaspring W.L.L., and advancements in their sepsis diagnostic test kit, SepsetME. The webinar will also cover a feasibility study for an antibacterial mouthwash in China and the development of new wound bandages. The company aims to address significant medical needs associated with antibiotic failure.